MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):281-285. doi: 10.15585/mmwr.mm6911a2.
Worldwide, tuberculosis (TB) is the leading cause of death from a single infectious disease agent (1), including among persons living with human immunodeficiency virus (HIV) infection (2). A World Health Organization (WHO) initiative, The End Tuberculosis Strategy, set ambitious targets for 2020-2035, including 20% reduction in TB incidence and 35% reduction in the absolute number of TB deaths by 2020 and 90% reduction in TB incidence and 95% reduction in TB deaths by 2035, compared with 2015 (3). This report evaluated global progress toward these targets based on data reported by WHO (1). Annual TB data routinely reported to WHO by 194 member states were used to estimate TB incidence and mortality overall and among persons with HIV infection, TB-preventive treatment (TPT) initiation, and drug-resistant TB for 2018 (1). In 2018, an estimated 10 million persons had incident TB, and 1.5 million TB-related deaths occurred, representing 2% and 5% declines from 2017, respectively. The number of persons with both incident and prevalent TB remained highest in the WHO South-East Asia and African regions. Decreases in the European region were on track to meet 2020 targets. Globally, among persons living with HIV, 862,000 incident TB cases occurred, and 1.8 million persons initiated TPT. Rifampicin-resistant or multidrug-resistant TB occurred among 3.4% of persons with new TB and 18% among persons who were previously treated for TB (overall, among 4.8% of persons with TB). The modest decreases in the number of persons with TB and the number of TB-related deaths were consistent with recent trends, and new and substantial progress was observed in increased TPT initiation among persons living with HIV. However, to meet the global targets for 2035, more intensive efforts are needed by public health partners to decrease TB incidence and deaths and increase the number of persons receiving TB curative and preventive treatment. Innovative approaches to case finding, scale-up of TB preventive treatment, use of newer TB treatment regimens, and prevention and control of HIV will contribute to decreasing TB.
全球范围内,结核病(TB)是单一传染病病原体导致死亡的首要原因(1),包括艾滋病毒(HIV)感染者(2)。世界卫生组织(WHO)的一项倡议《终结结核病战略》为 2020-2035 年设定了宏伟目标,包括到 2020 年结核病发病率降低 20%,结核病死亡人数绝对减少 35%,到 2035 年结核病发病率降低 90%,结核病死亡人数降低 95%,与 2015 年相比(3)。本报告根据世卫组织报告的数据(1)评估了这些目标的全球进展情况。194 个会员国定期向世卫组织报告的年度结核病数据用于估算 2018 年结核病总发病率和死亡率以及 HIV 感染者中的结核病发病率和死亡率、结核预防性治疗(TPT)的启动情况以及耐药结核病(1)。2018 年,估计有 1000 万人患有新发结核病,150 万人死于结核病相关疾病,与 2017 年相比,分别下降了 2%和 5%。在世卫组织东南亚和非洲区域,同时患有新发和已患结核病的人数最多。欧洲区域的下降趋势符合 2020 年的目标。在 HIV 感染者中,全球有 86.2 万例新发结核病病例,有 180 万人启动了 TPT。新出现的结核病患者中有 3.4%和以前接受过结核病治疗的患者中有 18%(总体为 4.8%)出现利福平耐药或耐多药结核病。结核病患者人数和结核病相关死亡人数的适度减少与最近的趋势一致,在 HIV 感染者中增加 TPT 启动方面取得了新的显著进展。然而,要实现 2035 年的全球目标,公共卫生伙伴需要更加努力,降低结核病发病率和死亡率,增加接受结核病治疗和预防治疗的人数。结核病病例发现的创新方法、扩大结核预防性治疗、使用新的结核病治疗方案以及预防和控制艾滋病毒,将有助于减少结核病。